Holen Sie sich die Stockscreener-App
26.55
0.49%
0.13
Handel nachbörslich:
27.07
0.52
+1.96%
Schlusskurs vom Vortag:
$26.42
Offen:
$26.9
24-Stunden-Volumen:
101.93K
Relative Volume:
2.56
Marktkapitalisierung:
$884.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.49%
1M Leistung:
-5.92%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$26.22
$27.65
1-Wochen-Bereich:
$26.22
$29.11
52-Wochen-Spanne:
$24.71
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Firmenname
Spyglass Pharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare SGP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
26.55 | 880.25M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-03 | Eingeleitet | Citigroup | Buy |
| 2026-03-03 | Eingeleitet | Jefferies | Buy |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Stifel | Buy |
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating By Investing.com - Investing.com Canada
SpyGlass Pharma reports positive 12-month Phase 1/2 BIM-IOL results with high drop-free rates - TradingView
SpyGlass Pharma reports positive 12-month glaucoma device trial data - Investing.com
SpyGlass Pharma reports positive 12-month glaucoma device trial data By Investing.com - Investing.com UK
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System - The Manila Times
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results For Its Innovative BIM-IOL System - marketscreener.com
Spyglass Pharma surges on public debut; Agomab falls - MSN
Spyglass Pharma (NASDAQ:SGP) Upgraded at Zacks Research - Defense World
Polsinelli Advises SpyGlass Pharma on Intellectual Property Matters in Initial Public Offering - The National Law Review
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit - Bitget
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at Citigroup - Defense World
Jefferies Initiates Coverage of SpyGlass Pharma (SGP) with Buy Recommendation - Nasdaq
Leerink initiates SpyGlass Pharma stock with Outperform rating By Investing.com - Investing.com Canada
Spyglass Pharma (NASDAQ:SGP) Now Covered by Stifel Nicolaus - MarketBeat
Jefferies initiates SpyGlass Pharma stock with buy rating on glaucoma drug - Investing.com Canada
Leerink Initiates SpyGlass Pharma at Outperform With $42 Price Target - marketscreener.com
Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target - marketscreener.com
Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential - Investing.com Canada
Spyglass Pharma (SGP) Stock Price, News & Analysis $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
Spyglass Pharma (SGP) Stock Trends and Sentiment 2026 $SGP - MarketBeat
Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders - Yahoo Finance
New Enterprise Associates 17, L.P. Increases Stake in SpyGlass P - GuruFocus
NEA 17 (SGP) converts preferred and buys 937,500 SpyGlass Pharma shares - Stock Titan
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering - Legal Desire Media and Insights
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma (Nasdaq: SGP) closes $172.5M IPO at $16 per share - Stock Titan
SpyGlass Pharma closes $172.5 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
SpyGlass Pharma closes $172.5 million IPO on NASDAQ - Investing.com South Africa
SpyGlass Pharma Announces Closing of Initial Public - GlobeNewswire
Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO - TipRanks
SpyGlass Pharma Raises $150 Million in Initial Public Offering - VisionMonday
SpyGlass Pharma, Inc. (SGP) Eps Diluted (TTM) - Zacks Investment Research
SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One - Smartkarma
Eye care firm SpyGlass Pharma soars 65% in trading debut - MSN
SpyGlass Pharma, Developer of Long-Acting Ocular Drug-Delivery Implants for Glaucoma and Other Chronic Eye Conditions, Files for Nasdaq Global Select Market IPO - TradingView
Eye Care Firm SpyGlass Pharma Soars 50% After $150 Million IPO - Bloomberg.com
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts - Intellectia AI
Spyglass Pharma shares surge 50% in Nasdaq debut By Investing.com - Investing.com Canada
SpyGlass PharmaSGPStock Price & News - The Motley Fool
SpyGlass Pharma raises $150 million in IPO priced at $16 per share - Investing.com Australia
SpyGlass Pharma Rings the Opening Bell - Nasdaq
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments - Intellectia AI
SpyGlass Pharma raises $150 million in IPO priced at $16 per share By Investing.com - Investing.com South Africa
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
Free float of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma Shares Rise in Nasdaq Debut - marketscreener.com
SGP IPO NewsChronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint - renaissancecapital.com
Finanzdaten der Spyglass Pharma Inc-Aktie (SGP)
Es liegen keine Finanzdaten für Spyglass Pharma Inc (SGP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):